ArticleBMC cancer2025
Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.
Yaqian Tan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleBMC cancer2025
Yaqian Tan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.